Skip to content

Study · Animal study (in vivo) · mouse · 2011

4 results

A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.

Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y

PloS one17 Jan 2011Cited by 68 (Europe PMC)

PMID21264226 (opens in a new tab)PMCIDPMC3022031 (opens in a new tab)DOI10.1371/journal.pone.0016259 (opens in a new tab)PepBankPUB-21264226
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Humanin (HN), a 24-residue peptide, was identified as a novel neuroprotective factor and shows anti-cell death activity against a wide spectrum of Alzheimer's disease (AD)-related cytotoxicities, including exposure to amyloid beta (Abeta), in vitro. We previously demonstrated that the injection of S14G-HN, a highly potent HN derivative, into brain ameliorated memory loss in an Abeta-injection mouse model. To fully understand HN's functions under AD-associated pathological conditions, we examined the effect of S14G-HN on triple transgenic mice harboring APP(swe), tau(P310L), and PS-1(M146V) that show the age-dependent development of multiple pathologies relating to AD. After 3 months of intranasal treatment, behavioral analyses showed that S14G-HN ameliorated cognitive impairment in male mice. Moreover, ELISA and immunohistochemical analyses showed that Abeta levels in brains were markedly lower in S14G-HN-treated male and female mice than in vehicle control mice. We also found the expression level of neprilysin, an Abeta degrading enzyme, in the outer molecular layer of hippocampal formation was increased in S14G-HN-treated mouse brains. NEP activity was also elevated by S14G-HN treatment in vitro. These findings suggest that decreased Abeta level in these mice is at least partly attributed to S14G-HN-induced increase of neprilysin level. Although HN was identified as an anti-neuronal death factor, these results indicate that HN may also have a therapeutic effect on amyloid accumulation in AD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male triple transgenic Alzheimer's disease mice, 3 months of intranasal S14G-HN, a humanin derivative, ameliorated cognitive impairment in behavioral analyses.

    In plain wordsIn male mice with Alzheimer's-like disease, a humanin derivative given through the nose for 3 months eased memory and thinking problems.

    Peptide
    Humanin
    Outcome
    DecreaseCognitive impairment in behavioral tests (male mice)
    Study

    mousen: not reported in source

    Triple transgenic Alzheimer's disease mice (APP swe, tau P310L, PS-1 M146V)
    Comparator
    Vehicle control
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    After 3 months of intranasal treatment, behavioral analyses showed that S14G-HN ameliorated cognitive impairment in male mice.
    1 context sentence
    Summary · context
    To fully understand HN's functions under AD-associated pathological conditions, we examined the effect of S14G-HN on triple transgenic mice harboring APP(swe), tau(P310L), and PS-1(M146V) that show the age-dependent development of multiple pathologies relating to AD.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male and female triple transgenic mice, S14G-HN treatment lowered brain amyloid beta levels compared with vehicle control mice.

    In plain wordsIn mice with Alzheimer's-like disease, a humanin derivative lowered amyloid beta in the brain compared with vehicle-treated mice.

    Peptide
    Humanin
    Outcome
    DecreaseBrain amyloid beta levels
    Study

    mousen: not reported in source

    Triple transgenic Alzheimer's disease mice (APP swe, tau P310L, PS-1 M146V)
    Comparator
    Vehicle control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, ELISA and immunohistochemical analyses showed that Abeta levels in brains were markedly lower in S14G-HN-treated male and female mice than in vehicle control mice.
    1 context sentence
    Summary · context
    To fully understand HN's functions under AD-associated pathological conditions, we examined the effect of S14G-HN on triple transgenic mice harboring APP(swe), tau(P310L), and PS-1(M146V) that show the age-dependent development of multiple pathologies relating to AD.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In triple transgenic mice, S14G-HN treatment increased the expression of neprilysin, an amyloid beta degrading enzyme, in the outer molecular layer of the hippocampal formation.

    In plain wordsIn mice with Alzheimer's-like disease, a humanin derivative raised levels of an enzyme that breaks down amyloid beta in part of the hippocampus.

    Peptide
    Humanin
    Outcome
    IncreaseHippocampal neprilysin expression
    Study

    mousen: not reported in source

    Triple transgenic Alzheimer's disease mice (APP swe, tau P310L, PS-1 M146V)
    Comparator
    Vehicle control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    We also found the expression level of neprilysin, an Abeta degrading enzyme, in the outer molecular layer of hippocampal formation was increased in S14G-HN-treated mouse brains.
    1 context sentence
    Summary · context
    To fully understand HN's functions under AD-associated pathological conditions, we examined the effect of S14G-HN on triple transgenic mice harboring APP(swe), tau(P310L), and PS-1(M146V) that show the age-dependent development of multiple pathologies relating to AD.
  4. 04LabIn vitro (cells)Mechanism

    In vitro, S14G-HN treatment elevated neprilysin activity.

    In plain wordsIn lab tests, a humanin derivative raised the activity of the enzyme neprilysin.

    Peptide
    Humanin
    Outcome
    IncreaseNeprilysin (NEP) activity in vitro
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NEP activity was also elevated by S14G-HN treatment in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.